Abivax

ABVX

Market cap $9.34B

Out with the old (tech), in with the new (healthcare). After several volatile weeks, it appears a full-fledged rotation has begun with investors fleeing previously high-flying tech winners in favor of underserved healthcare stocks.

Abivax SA Sponsored ADR (ABVX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Here is how Abivax SA Sponsored ADR (ABVX) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.

Abivax delivered outstanding phase 3 results for obefazimod in ulcerative colitis, with a 16.4% placebo-adjusted clinical remission rate. ABVX's safety profile is superior to JAK inhibitors and S1Ps, with minimal serious adverse events and no black-box warning expected. Following positive data and a $748M capital raise, I raise the target price to $136 and maintain a buy rating, citing ~30% upside.

ABIVAX Société Anonyme [NASDAQ: ABVX] is rated a Strong Buy with a $105 price target, driven by Obefazimod's best-in-class potential for ulcerative colitis (UC). ABVX's Obefazimod shows robust efficacy and differentiation in early Phase 3 trials, targeting a large, fast-growing inflammatory bowel disease market. Upcoming Phase 3 maintenance data in Q2 2026 is a major catalyst, with positive results likely to unlock significant upside for ABVX shares.

ABIVAX Société Anonyme (NASDAQ:ABVX ) Shareholder/Analyst Call October 6, 2025 9:00 AM EDT Company Participants Patrick Malloy - Senior Vice President of Investor Relations Marc M. de Garidel - CEO & Director Chris Rabbat - VP & Global Head of Medical Affairs Fabio Cataldi - Chief Medical Officer Conference Call Participants Marla C.

Abivax SA (NASDAQ:ABVX) shared additional clinical data on Monday for obefazimod at the United European Gastroenterology (UEG) Meeting.

Leading biotech stock Abivax jumped Monday on compelling test results for its experimental ulcerative colitis treatment.

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led to a pooled 16.4% (p

Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting